Literature DB >> 28240368

Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma.

Meera Mohan1, Rohan S Samant2, Donghoon Yoon1, Amy F Buros1, Antonio Branca1, Corey O Montgomery3, Richard Nicholas3, Larry J Suva4, Roy Morello5, Sharmilan Thanendrarajan1, Carolina Schinke1, Shmuel Yaccoby1, Frits van Rhee1, Faith E Davies1, Gareth J Morgan1, Maurizio Zangari1.   

Abstract

Osteolytic bone lesions are a hallmark of multiple myeloma (MM) bone disease. Bone destruction is associated with severely imbalanced bone remodeling, secondary to increased osteoclastogenesis and significant osteoblast suppression. Lytic lesions of the pelvis are relatively common in MM patients and are known to contribute to the increased morbidity because of the high risk of fracture, which frequently demands extensive surgical intervention. After observing unexpected radiological improvement in serial large pelvic CT assessment in a patient treated in a total therapy protocol, the radiographic changes of pelvic osteolytic lesions by PET/CT scanning in patients who received Total Therapy 4 (TT4) treatment for myeloma were retrospectively analyzed. Sixty-two (62) patients with lytic pelvic lesions >1 cm in diameter were identified at baseline PET/CT scanning. Follow-up CT studies showed that 27 of 62 patients (43%) with large baseline pelvic lesions achieved significant reaccumulation of radiodense mineralization at the lytic cortical site. The average size of lytic lesions in which remineralization occurred was 4 cm (range, 1.3 to 10 cm). This study clearly demonstrates that mineral deposition in large pelvic lesions occurs in a significant proportion of MM patients treated with TT4, potentially affecting patient outcomes, quality of life, and future treatment strategies.
© 2017 American Society for Bone and Mineral Research. © 2017 American Society for Bone and Mineral Research.

Entities:  

Keywords:  BONE HEALING; COLLAGEN; MATRIX MINERALIZATION; MULTIPLE MYELOMA; TUMOR-INDUCED BONE DISEASE

Mesh:

Substances:

Year:  2017        PMID: 28240368      PMCID: PMC5466479          DOI: 10.1002/jbmr.3111

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  29 in total

Review 1.  Bone disease in multiple myeloma.

Authors:  P I Croucher; J F Apperley
Journal:  Br J Haematol       Date:  1998-12       Impact factor: 6.998

2.  Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index.

Authors:  Evangelos Terpos; Richard Szydlo; Jane F Apperley; Evdoxia Hatjiharissi; Marianna Politou; John Meletis; Nora Viniou; Xenophon Yataganas; John M Goldman; Amin Rahemtulla
Journal:  Blood       Date:  2003-04-10       Impact factor: 22.113

3.  Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.

Authors:  Gareth J Morgan; Faith E Davies; Walter M Gregory; Alex J Szubert; Sue E Bell; Mark T Drayson; Roger G Owen; A John Ashcroft; Graham H Jackson; J Anthony Child
Journal:  Blood       Date:  2012-04-12       Impact factor: 22.113

4.  Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma.

Authors:  Shuji Ozaki; Osamu Tanaka; Shiro Fujii; Yuri Shigekiyo; Hirokazu Miki; Masahito Choraku; Kumiko Kagawa; Jin Asano; Kyoko Takeuchi; Ken-ichi Kitazoe; Toshihiro Hashimoto; Masahiro Abe; Toshio Matsumoto
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

Review 5.  Myeloma bone disease: recent advances in biology, diagnosis, and treatment.

Authors:  Orhan Sezer
Journal:  Oncologist       Date:  2009-03-13

6.  Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.

Authors:  Ya-Wei Qiang; Bart Barlogie; Stuart Rudikoff; John D Shaughnessy
Journal:  Bone       Date:  2007-12-27       Impact factor: 4.398

Review 7.  Skeletal complications of malignancy.

Authors:  R E Coleman
Journal:  Cancer       Date:  1997-10-15       Impact factor: 6.860

8.  Bone healing in multiple myeloma: a prospective evaluation of the impact of first-line anti-myeloma treatment.

Authors:  Maja Hinge; Kristian T Andersen; Thomas Lund; Henrik B Jørgensen; Paw C Holdgaard; Tina E Ormstrup; Lone L Østergaard; Torben Plesner
Journal:  Haematologica       Date:  2016-06-30       Impact factor: 9.941

9.  Review of 1027 patients with newly diagnosed multiple myeloma.

Authors:  Robert A Kyle; Morie A Gertz; Thomas E Witzig; John A Lust; Martha Q Lacy; Angela Dispenzieri; Rafael Fonseca; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew E Plevak; Terry M Therneau; Philip R Greipp
Journal:  Mayo Clin Proc       Date:  2003-01       Impact factor: 7.616

10.  Pathologic fractures of the acetabulum and the pelvis.

Authors:  M G Rock; K Harrington
Journal:  Orthopedics       Date:  1992-05       Impact factor: 1.390

View more
  1 in total

1.  Bone remineralization of lytic lesions in multiple myeloma - The Arkansas experience.

Authors:  Meera Mohan; Manoj Kumar; Rohan Samant; Rudy Van Hemert; Erming Tian; Shivang Desai; Frits van Rhee; Sharmilan Thanendrarajan; Carolina Schinke; Larry J Suva; Shobhit Sharma; Mohamed Milad; Samantha Kendrick; Maurizio Zangari
Journal:  Bone       Date:  2021-02-06       Impact factor: 4.398

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.